Cargando…

Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia

Australia was alerted to a possible increase in allergy-related adverse events following immunisation (AEFI) with 2015 seasonal trivalent influenza vaccines (TIV) by the Victorian state vaccine safety service, SAEFVIC. We describe SAEFVIC’s initial investigation and upon conclusion of the 2015 influ...

Descripción completa

Detalles Bibliográficos
Autores principales: Clothier, Hazel J, Crawford, Nigel, Russell, Melissa A, Buttery, Jim P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479975/
https://www.ncbi.nlm.nih.gov/pubmed/28552101
http://dx.doi.org/10.2807/1560-7917.ES.2017.22.20.30535
_version_ 1783245206154379264
author Clothier, Hazel J
Crawford, Nigel
Russell, Melissa A
Buttery, Jim P
author_facet Clothier, Hazel J
Crawford, Nigel
Russell, Melissa A
Buttery, Jim P
author_sort Clothier, Hazel J
collection PubMed
description Australia was alerted to a possible increase in allergy-related adverse events following immunisation (AEFI) with 2015 seasonal trivalent influenza vaccines (TIV) by the Victorian state vaccine safety service, SAEFVIC. We describe SAEFVIC’s initial investigation and upon conclusion of the 2015 influenza vaccination programme, to define the signal event and implications for vaccine programmes. Allergy-related AEFI were defined as anaphylaxis, angioedema, urticaria or generalised allergic reaction. Investigations compared 2015 TIV AEFI reports to previous years as proportions and reporting risk (RR) per 100,000, stratified by influenza vaccine brand. The initial investigation showed an increased proportion of allergy-related AEFI compared with 2014 (25% vs 12%), predominantly in adults, with insufficient clinical severity to alter the programme risk-benefit. While overall TIV AEFI RR in 2015 was similar to previous years (RR: 1.07, 95% confidence interval (CI): 0.88–1.29), we identified a near-doubling RR for allergy-related AEFI in 2015 (RR: 1.78, 95% CI: 1.14­– 2.80) from 2011 to 2014 with no difference by vaccine brand or severity increase identified. This increase in generalised allergy-related AEFI, across all used vaccine brands, supports evidence of variable reactogenicity arising from influenza vaccine strain variations. This investigation underlines the importance of effective seasonal influenza vaccine pharmacovigilance.
format Online
Article
Text
id pubmed-5479975
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-54799752017-07-07 Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia Clothier, Hazel J Crawford, Nigel Russell, Melissa A Buttery, Jim P Euro Surveill Surveillance and Outbreak Report Australia was alerted to a possible increase in allergy-related adverse events following immunisation (AEFI) with 2015 seasonal trivalent influenza vaccines (TIV) by the Victorian state vaccine safety service, SAEFVIC. We describe SAEFVIC’s initial investigation and upon conclusion of the 2015 influenza vaccination programme, to define the signal event and implications for vaccine programmes. Allergy-related AEFI were defined as anaphylaxis, angioedema, urticaria or generalised allergic reaction. Investigations compared 2015 TIV AEFI reports to previous years as proportions and reporting risk (RR) per 100,000, stratified by influenza vaccine brand. The initial investigation showed an increased proportion of allergy-related AEFI compared with 2014 (25% vs 12%), predominantly in adults, with insufficient clinical severity to alter the programme risk-benefit. While overall TIV AEFI RR in 2015 was similar to previous years (RR: 1.07, 95% confidence interval (CI): 0.88–1.29), we identified a near-doubling RR for allergy-related AEFI in 2015 (RR: 1.78, 95% CI: 1.14­– 2.80) from 2011 to 2014 with no difference by vaccine brand or severity increase identified. This increase in generalised allergy-related AEFI, across all used vaccine brands, supports evidence of variable reactogenicity arising from influenza vaccine strain variations. This investigation underlines the importance of effective seasonal influenza vaccine pharmacovigilance. European Centre for Disease Prevention and Control (ECDC) 2017-05-18 /pmc/articles/PMC5479975/ /pubmed/28552101 http://dx.doi.org/10.2807/1560-7917.ES.2017.22.20.30535 Text en This article is copyright of The Authors, 2017. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Surveillance and Outbreak Report
Clothier, Hazel J
Crawford, Nigel
Russell, Melissa A
Buttery, Jim P
Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia
title Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia
title_full Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia
title_fullStr Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia
title_full_unstemmed Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia
title_short Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia
title_sort allergic adverse events following 2015 seasonal influenza vaccine, victoria, australia
topic Surveillance and Outbreak Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479975/
https://www.ncbi.nlm.nih.gov/pubmed/28552101
http://dx.doi.org/10.2807/1560-7917.ES.2017.22.20.30535
work_keys_str_mv AT clothierhazelj allergicadverseeventsfollowing2015seasonalinfluenzavaccinevictoriaaustralia
AT crawfordnigel allergicadverseeventsfollowing2015seasonalinfluenzavaccinevictoriaaustralia
AT russellmelissaa allergicadverseeventsfollowing2015seasonalinfluenzavaccinevictoriaaustralia
AT butteryjimp allergicadverseeventsfollowing2015seasonalinfluenzavaccinevictoriaaustralia